New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
09:14 EDTOXGNOxigene regains compliance with NASDAQ listing rule
Oxigene announced that on January 14 Nasdaq notified the company that it regained compliance with the minimum $1.00 per share closing bid price requirement for continued listing. As a result of satisfying the minimum bid price requirement, this matter is now closed.
News For OXGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 3, 2016
09:05 EDTOXGNOXiGENE announces FDA approval of protocol for FOCUS phase 2/3 study of CA4P
OXiGENE announced that the FDA has approved the protocol for FOCUS, OXiGENE's phase 2/3 study of CA4P for the treatment of platinum-resistant ovarian cancer. FOCUS will test whether CA4P, the company's lead investigational drug, improves progression-free survival when combined with bevacizumab and chemotherapy. If the trial is successful, data from FOCUS would be used as the basis for a new drug application to the FDA.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use